

# Circulatory support in the Sick Child

Avinash C Shukla  
Department of Anesthesia  
Childrens Hospital Boston

## *Circulatory support in the Sick Child*

- Increased sympathetic drive
- Elevated catecholamines
- Continuing stimulation
- Exacerbated by exogenous agonist use
- Decreased effect
- Desensitization

## *Circulatory support in the Sick Child*

- Endogenous catecholamines
- Mechanism of Desensitization
- Pathological causes
- Therapeutic Options

## *Endogenous catecholamines*

- Stimulus: Sympathetic drive
- Origin: Adrenal medulla
- Delivery: Bloodstream
- Catecholamines: 80% epinephrine  
20% norepinephrine
- Action: via adrenergic receptors

## *Endogenous catecholamines*

- 1913 Dale demonstrated epinephrine action
- 1948 Ahlquist defined two receptor subtypes:  $\alpha$  and  $\beta$
- Potency  
 $\alpha$ : Norepi > Epi > Iso  
 $\beta$ : Iso > Epi > Norepi

### *Endogenous catecholamines*

- 2003: 10 subtypes
- 4 Beta, 6 Alpha adrenoceptors
- $\beta_1$  : Cardiac
- $\beta_2$  : Smooth Muscle
- $\beta_3$  : Adipose tissue
- $\beta_4$  : Cardiac

### *Endogenous catecholamines*

$\beta_1$  Receptor:

- Agonism  $\rightarrow$  Gs protein activation  $\rightarrow$  Adenyl cyclase activation  $\rightarrow$   $\uparrow$  cAMP
- cAMP  $\rightarrow$  PKA activation  $\rightarrow$  L-type Ca channel opening  $\rightarrow$   $\uparrow$  Ca influx

### *Endogenous catecholamines*

$\beta_2$  Receptor:

- Agonism  $\rightarrow$  Gs protein activation  $\rightarrow$  Adenyl cyclase activation  $\rightarrow$   $\uparrow$  cAMP
- cAMP  $\rightarrow$  PKA activation  $\rightarrow$  L-type Ca channel opening  $\rightarrow$   $\uparrow$  Ca influx

### *Endogenous catecholamines*

$\beta_2$  Receptor:

- Agonism  $\rightarrow$  phosphorylation of myosin light chain kinase  $\rightarrow$  smooth muscle relaxation
- Agonism  $\rightarrow$  Gi protein activation  $\rightarrow$   $\downarrow$  cAMP

### *Endogenous catecholamines*

$\alpha_1$  Receptor:

- Agonism  $\rightarrow$  Gq protein activation  $\rightarrow$  PLC activation
- PI  $\rightarrow$  DAG + IP<sub>3</sub>
- IP<sub>3</sub>  $\rightarrow$  sequestered Ca influx

### *Desensitization*

- Continuous stimulation leads to decreased response = DESENSITIZATION
- Mainly  $\alpha_1$  and  $\beta_1$
- Homologous - Agonist specific
- Heterologous - Not agonist specific

### *Desensitization*

- Three distinct but interrelated processes
- Receptor/G protein uncoupling
- Receptor sequestration
- Downregulation

### *Desensitization*

- Receptor/G protein uncoupling
- Rapid
- Receptor Phosphorylation
- $\beta$ -arrestin complex formation
- Uncoupled state

### *Desensitization*

- Sequestration
- Several Minutes
- $\beta$ -arrestin complex binds to Clathrin
- Whole complex sequestered
- Receptors recycled/degraded

### *Desensitization*

- Downregulation
- Several hours and is irreversible
- Two processes
  1. Sequestered receptors degraded
  2. cAMP Response Element Binding protein activated

### *Desensitization*

- Downregulation
- CREB protein inhibits RNA polymerase for receptor protein
- Recovery requires receptor synthesis

### *Desensitization*

- In Summary
- Continuing receptor stimulation leads to an ever-decreasing response which ultimately causes irreversible destruction of receptors.

### *Desensitization*

- Zeiders JL et al
- Agonist induced sensitization of beta-adrenoceptor signalling in neonatal rat heart: expression and catalytic activity of adenylyl cyclase
- *J Pharmacol Exp Ther* 1999;291:503-510

### *Desensitization*

- Rats given isoproterenol daily for 4 days
- Rats aged 6,15,25 days and adult.
- Cardiac membrane evaluated day 5 to isoproterenol stimulation
- 6 day old rat exhibited sensitization and enhanced response.
- All others desensitized.

### *Pathological Causes*

- Exogenous Catecholamines
- Heart Failure
- Hypoxia
- Hypertrophy and Outflow Obstruction
- Sepsis

### *Low Cardiac Output/Heart Failure*

- Inadequate Preload: Haemorrhage, Dehydration
- Increased Afterload: Hypertension, Severe polycythaemia
- Decreased Contractility: Cardiomyopathy

### *Low Cardiac Output/Heart Failure*

- Wu JR et al
- Circulating Noradrenaline and beta-adrenergic receptors in children with congestive heart failure
- *Acta paediatr* 1996;85:923-927

### *Low Cardiac Output/Heart Failure*

- 94 non cyanotic children with heart disease
- 43 with CHF
- 52 without CHF
- Increased Norepi levels and decreased beta receptor density in CHF group
- Both returned to baseline post repair

### *Low Cardiac Output/Heart Failure*

- Wu JR
- Reduction in lymphocyte beta adrenergic receptor density in infants and children with heart failure secondary to congenital heart disease
- *Am J Cardiol* 1996;77:170-174

### *Low Cardiac Output/Heart Failure*

- 91 children with non cyanotic heart disease
- Degree of L → R shunt and PA pressure correlated closely with plasma Norepi levels
- and inversely with beta receptor density

#### *Conclusion*

- Congestive heart failure causes norepinephrine induced homologous desensitization

### *Hypoxia*

- Antezana et al
- Adrenergic status of humans during prolonged exposure to the altitude of 6542m.
- *J Appl Phys* 1994;76:1055-1059

### *Hypoxia*

- 10 subjects
- Studied at sea level, 1 and 3 weeks at altitude
- Measurements taken:
  - Plasma Norepinephrine
  - Response to Isoproterenol
  - Density of lymphocyte beta receptors

### *Hypoxia*

#### *Conclusion*

- Increasing plasma norepinephrine levels
- Decreasing response to isoproterenol
- Response did not improve with acclimatization
- Density of beta receptors reduced by 45%

### *Hypoxia*

- Mardon K et al
- Effects of 5-day hypoxia on cardiac adrenergic neurotransmission in rats
- *J Appl Physiol* 1998;85:890-897

### *Hypoxia*

- 32 Male Wistar rats
- 5 days in hypobaric chamber
- Comparison with normoxic rats

#### *Results*

- Plasma Norepi levels increased
- Norepi reuptake reduced 35%
- Response to isoproterenol reduced by 35%

### *Hypoxia*

#### *Conclusion*

- Chronic hypoxia leads to a loss of specific uptake 1 carrier protein for Norepinephrine
- This leads to catecholamine induced desensitization

### *Hypoxia*

- Contrary Findings
- Sun LS et al
- Right ventricular infundibular beta adrenoceptor complex in tetralogy of fallot patients
- *Pediatr Res* 1997;42:12-16

### *Hypoxia*

- Compared symptomatic vs asymptomatic children with TOF preoperatively

#### *Results*

- Symptomatic children had increased receptor density and enhanced agonist response compared with asymptomatic
- Therapy with beta blockers validates this

### *Outflow Obstruction*

- Galal O et al
- Sympathetic activity in children undergoing balloon valvuloplasty of pulmonary stenosis
- *Pediatr Res* 1996;39:774-778

### *Outflow Obstruction*

- Determined density of lymphocyte beta adrenoceptors pre and post dilation
- Children having PDA occlusion as controls
- Pre: 23% decreased receptor density
- 10 Minutes post: Equal density to controls

#### *Mechanism of desensitization:*

- Wall stress without receptor agonism

### *Sepsis*

- 5 per 1,000 children < 1 require in-patient therapy for sepsis per year
- Cost to the nation: \$1.1 billion/year
- Cardiac failure predominant cause of death

### *Sepsis*

- Joe EK et al
- Regulation of cardiac myocyte contractile function by inducible nitric oxide synthase: Mechanisms of contractile depression by nitric oxide
- *J Mol Cell Cardiol* 1998;30:303-315

### *Sepsis*

- Study conducted at the B and W
- Incubated cardiac myocytes
- Added LPS-activated macrophages
- Examined after 20 hours

#### *Results*

- Inducible NO synthase activity increased
- Increased NO production

## *Sepsis*

### *Results*

- Reduced response to isoproterenol
- NOS activity did not affect receptor density or adenylyl cyclase activity

### *Conclusion*

- NO inhibited cAMP via cGMP
- NO synthase inhibitor reversed the trend

### *Desensitization*

- Thus numerous pathological conditions result in desensitization.
- How to proceed?
- 1. Mechanical Support?
- 2. Non adrenergic receptor mediated inotropic support

### *Therapeutic Options*

- Phosphodiesterase Inhibitors
- Tri-iodothyronine
- Insulin
- Growth Hormone
- Digoxin

### *Phosphodiesterase Inhibitors*

- Non catecholaminergic inotropic agents
- Amrinone, Milrinone and Enoximone
- Mechanism of action
- Phosphodiesterases degrade cAMP to 5AMP
- Inhibition leads to increased cAMP
- Increased Ca and increased contractility

### *Phosphodiesterase Inhibitors*

- Response related to increased cAMP not phosphodiesterase inhibition per se.
- Greatest effect if increased endogenous or exogenous catecholamine present.
- Synergy with  $\beta_1$  agonists
- Greatest synergy in neonates
- Significant positive effect on their own



### *Phosphodiesterase Inhibitors*

- *Advantages*
- Increased contractility
- Myocardial oxygen consumption unchanged
- Afterload reduction from RV and LV
- Improved coronary perfusion
- *Disadvantages*
- Inhibition of platelet aggregation

### *Phosphodiesterase Inhibitors*

- Enoximone
- Loading Dose: 0.5mg/kg over 1 hour
- Infusion: 10 mic/kg/min
  
- Milrinone
- Loading Dose: 0.05mg/kg over 1 hour
- Infusion: 0.5-1.5 mic/kg/min

### *Triiodothyronine*

- T<sub>3</sub> essential for maturation of sarcolemmal Ca channels, myosin, actin and troponin
- Hypothyroid rats show :-  
Decreased beta receptor  
Decreased Gs protein density  
Increased Gi receptor density

### *Triiodothyronine*

- 80% produced by monoiodination of T<sub>4</sub>
- T<sub>4</sub> → T<sub>3</sub> inhibited by:  
Surgery, CPB, hypothermia, catecholamines, glucocorticoids, propranolol and amiodarone

### *Triiodothyronine*

#### *Nucleus Mediated Effects*

- Increase in mitochondrial density
- Increase in mitochondrial respiration
- Increase in contractile protein synthesis
- Upregulation of beta adrenoceptors

### *Triiodothyronine*

#### *Extranuclear Effects*

- Increase in sarcolemmal glucose transport
- Stimulation of L-type calcium channels
- Increase in SRCaATpase activity → improved calcium reuptake → improved diastolic relaxation

### *Triiodothyronine*

#### *Advantages*

- Increased contractility
- Myocardial oxygen consumption unchanged
- Synergy with beta agonists
- Upregulation of beta receptors
- Reversal of depressed contractility secondary to desensitization

### *Triiodothyronine*

- Bettendorf M et al
- Tri-iodothyronine treatment in children after cardiac surgery: a double-blind, randomised, placebo-controlled study
- *Lancet* 2000;356:529-534

### *Triiodothyronine*

- 40 Children
- T<sub>3</sub> group - 2mic/kg day 1, 1mic/kg to day 12
- Simple and complex cardiac surgery

#### *Results*

- Better myocardial function and decreased ITU requirement in T<sub>3</sub> group
- No delay in recovery of thyroid function

### *Insulin*

#### *Normal resting cardiac metabolism*

- 60-70% Free fatty acids, 30-40% Glucose
- Glucose – less ATP, more efficient
- FFA – more ATP, less efficient
- Substrate utilised determined by relative plasma levels overall
- Glucose preferential if myocardium stressed

### *Insulin*

- Use of insulin based on two principles:
  1. Insulin stimulates myocardial Na/K ATPase, increasing K reuptake thus stabilising membrane.
  2. ATP produced from glucose metabolism preferentially used to support ion pumps.
- This improves calcium homeostasis and functional recovery

### *Insulin*

#### *Results of adult studies*

- Decreased myocyte excitability
- Improved systolic and diastolic function with little increase in oxygen consumption
- Synergy with beta agonists
- Decrease in systemic vascular resistance
- Studies in children awaited

### *Growth Hormone*

- Probably acts via insulin-like growth factors I and II.
- IGF I crucial for development of neonatal myocardium

#### *Probable mechanism*

- Increase in contractile protein synthesis
- Increase in calcium channel activity
- Increase in myocardial calcium sensitivity

### *Growth Hormone*

#### *Overall*

- Beneficial short term effects seen in adult heart failure
- Increased longer term mortality seen secondary to derangement of immune function in adults

### *Digoxin*

#### *Mechanism of action*

- Beta stimulation increases PKA activity
- Resultant increase in Na/K ATPase activity
- Digoxin inhibits pump action
- Decreased need to use Na/Ca pump
- Increased intracellular calcium
- Improved contractility

### *Digoxin*

- Advantages
- Children with dysrhythmia induced ventricular dysfunction
- Less evidence for beneficial effect if patient in sinus rhythm

### *New Agents*

- Vasopressin
- Nesiritide
- Levosimendan
- Fenoldopam

### *Conclusion*

#### *Treatment of the sick child*

1. Correction of metabolic abnormalities
2. Treatment of any underlying cause
3. Optimisation of heart rate, preload and afterload
4. Use of combination pharmacological therapy
5. Mechanical support